“As I see it you should not expect any significant contribution from Selincro. The contribution from this drug will be very limited in 2013,” says Sydbank analyst, Søren Løntoft Hansen, following last week’s European approval of the Selincro, a pill to treat alcohol addiction.
“The drug will have a relatively slow penetration. What will have an effect in 2013 and 2014 are the costs connected with penetrating the relevant markets for the alcohol pill. It will take its toll as far as costs are concerned to launch the drug and spread the message about the benefits of the pill to doctors,” the analyst points out.